ERBB2 and breast cancer: When comparing tucatinib and a placebo in combination with trastuzumab and capecitabine to treat HER2-positive breast cancer patients, the HER2 CLIMB study demonstrated that both the PFS and OS were significantly longer in the tucatinib group [128].